JP2009532338A5 - - Google Patents

Download PDF

Info

Publication number
JP2009532338A5
JP2009532338A5 JP2009500598A JP2009500598A JP2009532338A5 JP 2009532338 A5 JP2009532338 A5 JP 2009532338A5 JP 2009500598 A JP2009500598 A JP 2009500598A JP 2009500598 A JP2009500598 A JP 2009500598A JP 2009532338 A5 JP2009532338 A5 JP 2009532338A5
Authority
JP
Japan
Prior art keywords
alkyl
amino
hydroxy
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/064002 external-priority patent/WO2007106869A1/en
Publication of JP2009532338A publication Critical patent/JP2009532338A/ja
Publication of JP2009532338A5 publication Critical patent/JP2009532338A5/ja
Pending legal-status Critical Current

Links

JP2009500598A 2006-03-14 2007-03-14 Psmaのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法 Pending JP2009532338A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78221106P 2006-03-14 2006-03-14
PCT/US2007/064002 WO2007106869A1 (en) 2006-03-14 2007-03-14 Peptidomimetic inhibitors of psma,compounds comprising them, and methods of use

Publications (2)

Publication Number Publication Date
JP2009532338A JP2009532338A (ja) 2009-09-10
JP2009532338A5 true JP2009532338A5 (cg-RX-API-DMAC10.html) 2011-04-28

Family

ID=38229662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009500598A Pending JP2009532338A (ja) 2006-03-14 2007-03-14 Psmaのペプチド模倣体阻害剤、それらを含む化合物、およびそれらの使用方法

Country Status (9)

Country Link
US (3) US7696185B2 (cg-RX-API-DMAC10.html)
EP (1) EP1999136B1 (cg-RX-API-DMAC10.html)
JP (1) JP2009532338A (cg-RX-API-DMAC10.html)
CN (1) CN101443340B (cg-RX-API-DMAC10.html)
AU (1) AU2007226542B2 (cg-RX-API-DMAC10.html)
CA (1) CA2645809C (cg-RX-API-DMAC10.html)
ES (1) ES2397973T3 (cg-RX-API-DMAC10.html)
PL (1) PL1999136T3 (cg-RX-API-DMAC10.html)
WO (1) WO2007106869A1 (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002529A2 (en) 2007-06-26 2008-12-31 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
DK2187965T3 (da) 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
US20110288152A1 (en) * 2008-10-17 2011-11-24 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2010149666A1 (en) * 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
EP2338892A1 (en) * 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
CA2790577A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
JP5657902B2 (ja) * 2010-03-17 2015-01-21 株式会社コスモステクニカルセンター ポリオキシアルキレンステロールエーテル誘導体及び/又はポリオキシアルキレンスタノールエーテル誘導体、及びそれを含有する外用剤組成物
WO2012064914A2 (en) * 2010-11-12 2012-05-18 Washington State University Research Foundation Peptidomimetic inhibitors of psma
PL2721039T3 (pl) * 2011-06-15 2018-06-29 Cancer Targeted Technology Llc Chelatowane inhibitory PSMA
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
KR102318999B1 (ko) 2012-11-15 2021-10-29 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
SMT202300035T1 (it) 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
EP2842578B1 (en) * 2013-08-27 2018-06-27 GILUPI GmbH Diagnostic device for the detection of biomarkers
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
WO2016028700A1 (en) * 2014-08-18 2016-02-25 Washington State University Tunable ph-sensitive linker for controlled drug release
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US9808538B2 (en) * 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
MX392700B (es) 2016-08-10 2025-03-11 Cancer Targeted Tech Llc Inhibidores de antígeno de la membrana específico para la próstata (psma) quelados.
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
IL287989B2 (en) * 2019-05-13 2025-07-01 Bracco Imaging Spa Modified cyanine dyes and their conjugates
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
CN113117100B (zh) * 2019-12-31 2024-03-01 广东精观生物医药科技有限公司 一种靶向psma的荧光分子探针及其制备方法和应用
CN111675747B (zh) * 2020-07-30 2021-04-27 中国医学科学院医药生物技术研究所 抗肿瘤药物和用途
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US782211A (en) 1904-05-23 1905-02-07 George W Sturgis Vending-wagon.
JP2002515040A (ja) * 1996-06-17 2002-05-21 ギルフォード・ファーマシューティカルズ・インコーポレイテッド Naaladアーゼ阻害剤を用いる癌治療方法
AU4322102A (en) * 2000-11-20 2002-06-18 Eastern Virginia Med School Methods and devices for the quantitative detection of prostate specific membraneantigen and other prostatic markers
CA2436408A1 (en) * 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
EP1519747A4 (en) * 2002-01-28 2006-03-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)

Similar Documents

Publication Publication Date Title
KR102658933B1 (ko) 이중 표적화 화합물 및 이의 제조 방법과 응용
ES2397973T3 (es) Inhibidores peptidomiméticos del PSMA, compuestos que los comprenden y métodos de utilización
US8765096B2 (en) Methods and compositions for treating and diagnosing kidney disease
JP2016153410A5 (cg-RX-API-DMAC10.html)
US20210206774A1 (en) Molecular containers and methods of making and using same
US7998462B2 (en) Linkers for anchoring targeting ligands
CN103260652B (zh) 显示不依赖于浓度的响应性的cest系统
US20100183658A1 (en) Novel Compounds for Enhancing MHC Class II Therapies
JP2019519530A (ja) ペグ化されたカルフィルゾミブ化合物
JP2010174013A (ja) 組織ダメージの治療と予防
US20250177540A1 (en) Stable compositions of pegylated carfilzomib compounds
JP2014516993A5 (cg-RX-API-DMAC10.html)
AU2021259858B2 (en) GPER proteolytic targeting chimeras
KR20120047263A (ko) ε­폴리라이신 결합체 및 이의 용도
US10702546B2 (en) Bile acid oligomer conjugate for novel vesicular transport and use thereof
JP2011523669A (ja) 生分解性金属キレート化ポリマーおよびワクチン
RU2012124266A (ru) Хелаты марганца и их применение в качестве контрастных агентов в магнитно-резонансной визуализации (mpb)
US11414455B2 (en) Toll-like receptor 2 ligands and methods of making and using thereof
US20240190790A1 (en) Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
CN105188703A (zh) 荧光-hap:用于细胞中的hbv核的诊断性染色剂
Urbanovsky et al. Lanthanide complexes of DO3A–(Dibenzylamino) methylphosphinate: effect of Protonation of the Dibenzylamino Group on the water-exchange rate and the binding of human serum albumin
JP7114074B2 (ja) 画像化のためのニトロキシドを含むアミロイド結合剤およびその治療的使用
CA2739445A1 (en) Site specific n-terminal modifications of proteins and conjugate formation
JP2013532664A5 (cg-RX-API-DMAC10.html)
JP2014500268A5 (cg-RX-API-DMAC10.html)